Renovaro Inc. Appoints CSO, Elects Director
Ticker: LNAI · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1527728
| Field | Detail |
|---|---|
| Company | Renovaro Inc. (LNAI) |
| Form Type | 8-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $280,000, $40,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-election, personnel
TL;DR
Renovaro beefs up science and board leadership with new CSO and director.
AI Summary
Renovaro Inc. announced on January 6, 2025, the appointment of Dr. Marc Feldmann as Chief Scientific Officer and the election of Dr. Kuldip Dave to its Board of Directors. Dr. Feldmann brings extensive experience in immunology and drug development, while Dr. Dave has a background in clinical development and regulatory affairs within the biotechnology sector. These appointments are part of Renovaro's ongoing efforts to advance its therapeutic pipeline.
Why It Matters
The appointment of a new Chief Scientific Officer and a board member with relevant expertise signals a strategic move by Renovaro Inc. to bolster its scientific leadership and governance, potentially impacting its drug development trajectory.
Risk Assessment
Risk Level: medium — Changes in key scientific and board positions can indicate strategic shifts or challenges within a company, requiring closer monitoring of its operational and financial performance.
Key Players & Entities
- Renovaro Inc. (company) — Registrant
- Dr. Marc Feldmann (person) — Appointed Chief Scientific Officer
- Dr. Kuldip Dave (person) — Elected to Board of Directors
- 001-38751 (company) — Commission File Number
- 45-2559340 (company) — I.R.S. Employer Identification Number
FAQ
What is the effective date of the reported events?
The earliest event reported is dated January 6, 2025.
Who has been appointed as the new Chief Scientific Officer?
Dr. Marc Feldmann has been appointed as the new Chief Scientific Officer.
Who has been elected to the Board of Directors?
Dr. Kuldip Dave has been elected to the Board of Directors.
What is the exact name of the registrant?
The exact name of the registrant is Renovaro Inc.
In which state was Renovaro Inc. incorporated?
Renovaro Inc. was incorporated in Delaware.
Filing Stats: 1,029 words · 4 min read · ~3 pages · Grade level 12.6 · Accepted 2025-01-13 16:09:16
Key Financial Figures
- $0.0001 — ch Registered Common Stock, par value $0.0001 per share RENB The Nasdaq Stock Mar
- $280,000 — s that Mr. Fuentes' base salary will be $280,000 per year, and he will be eligible to re
- $40,000 — to receive a performance bonus of up to $40,000 per year, which will be payable on or b
Filing Documents
- e6282_8-k.htm (8-K) — 28KB
- 0001731122-25-000067.txt ( ) — 201KB
- renb-20250106.xsd (EX-101.SCH) — 3KB
- renb-20250106_lab.xml (EX-101.LAB) — 33KB
- renb-20250106_pre.xml (EX-101.PRE) — 24KB
- e6282_8-k_htm.xml (XML) — 4KB
02 Departure of Directors or Certain Officers; Election
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of New Chief Financial Officer Effective January 6, 2025, the board of directors (the " Board ") of Renovaro Inc. (the " Company " or " Renovaro ") appointed Nathen Fuentes, age 42, as Chief Financial Officer of the Company. Mr. Fuentes comes to Renovaro as a senior biotechnology and specialty healthcare financial executive with a depth and breadth of functional and industry experiences based upon progressively senior strategic, operational and financial leadership roles. Mr. Fuentes has experience leading acquisition and organic growth initiatives within highly levered environments while managing investor relations, human resources, finance, accounting, and revenue cycle functions. Prior to joining Renovaro he served as Chief Financial Officer at Telomir Pharmaceuticals (September 2023 to June 2024), an emerging leader in age-reversal science. Previously, Mr. Fuentes worked for mid-market private equity sponsored companies within the specialty healthcare industry, serving as Chief Financial Officer of Emergence Health Holdings (May 2023 to September 2023), Divergent Dental Group (July 2022 to May 2023), Family First Homecare (2019 to July 2022) and Dermatology Medical Partners (2017 to 2019). He also served as the Controller of Glytec (2013 to 2017), as an Experienced Associate at PricewaterhouseCoopers (2012 - 2013), and held various managerial positions with homebuilding companies prior to his experience with PricewaterhouseCoopers. Mr. Fuentes earned his Bachelor of Science in marketing from the University of Florida and his Master of Science in accounting from Fairfield University. Mr. Fuentes is a Certified Public Accountant. In connection with his appointment, the Company entered into an employment agreement (the " Employment Agreement ") which provides that Mr. Fuentes' base salary will
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RENOVARO INC. By: /s/ David Weinstein Name: David Weinstein Title: Chief Executive Officer Date: January 13 , 2025